Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 7/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995197 | 0.91 | MLNR (0.63) | MLNRKCNH2KMT2AMEN1NPC1 | |
| SCHEMBL2853580 | 0.87 | MLNR (0.52) | MLNRKCNH2KMT2AMEN1NPC1 | |
| SCHEMBL1998342 | 0.87 | MLNR (0.49) | MLNRKCNH2KMT2AMEN1NPC1 | |
| SCHEMBL2003276 | 0.87 | MLNR (0.49) | MLNRKCNH2KMT2AMEN1NPC1 | |
| SCHEMBL13954897 | 0.85 | CCR1 (0.59) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL2002043 | 0.85 | MLNR (0.46) | MLNRKCNH2KMT2AMEN1NPC1 | |
| SCHEMBL1996025 | 0.84 | CCR1 (0.45) | MLNRCCR1MMP13GPR119FPR3 | |
| SCHEMBL1996928 | 0.84 | GPR119 (0.49) | MLNRCCR1GPR119 | |
| SCHEMBL1999297 | 0.81 | MLNR (0.42) | MLNRKCNH2CCR1GPR119 | |
| SCHEMBL4134226 | 0.80 | MLNR (0.45) | MLNRCCR1GPR119FPR3GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| WO-2009068552-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | MLNR 12/4885KCNH2 2812/4885KMT2A 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.